To include your compound in the COVID-19 Resource Center, submit it here.

Fate reports initial Phase I data for Fate-NK100 in AML

Fate Therapeutics Inc. (NASDAQ:FATE) reported preliminary data from 2 patients with relapsed or refractory acute myelogenous leukemia (AML) in the Phase I VOYAGE trial evaluating single doses of

Read the full 283 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE